Company News
IDEAYA Biosciences Stock Surges 27% on Trial
IDEAYA Biosciences shares jumped 27% on Monday after its Phase 2/3 OptimUM‑02 trial met primary endpoint in metastatic uveal melanoma.
Median progression‑free survival improved to 6.9 months versus 3.
